Ph.D., Non-Executive Chairman
Ian was appointed a Director on 24 November 2014 and as Non-Executive Chairman on 11 May 2015. He is also Non-Executive Chairman of Cytox Group Limited who provide risk assessment and stratification tools for Alzheimers disease and dementia, and Non-Executive Chairman of Aptamer Group Plc a leader in the provision of aptamer discovery selection services and the development of aptamer-based reagents. Dr Gilham was formerly Chief Executive Officer of Axis-Shield Plc.
Chief Executive Officer
James was appointed a Director and Chief Executive on 11th September 2023 and brings extensive commercial and operational experience at a senior level through a successful career with established diagnostic companies such as Cepheid, Beckman Coulter, and Roche Diagnostics. Also, through serving as an executive board member of the British In Vitro Diagnostics Association (BIVDA) and representing the trade body as part of the NHS Supplier Board. The Board believes James’ experience, especially his extensive involvement in selling into the NHS, will be valuable as the Company expands its commercial footprint and opportunities within the UK and more widely.
Chief Financial Officer
Russ was appointed Chief Financial Officer on 7th April 2022. He has over 25 years of international experience across multiple sectors including life-sciences, technology and the industrials. Prior to joining genedrive, he spent 10 years as Finance Director at Driver Group plc, an AIM quoted company operating in the engineering and construction industry. Russ has been CFO of several private companies in recent years and is a qualified Accountant and Treasury professional.
Ph.D., Chief Scientific Officer
Gino was appointed a Director and Chief Scientific Officer on 11th September 2023. He has considerable experience in the development of molecular diagnostic technologies and systems and has been the R&D Director at genedrive since 2015 and its predecessor Epistem since 2011. Prior to that Gino served as Associate Director for clinical translational genomics at Wyeth and Pfizer. Gino has been a key driver in the development of the genedrive® system and point of care pharmacogenetic testing in emergency healthcare.
Tom has 35 years of global sales and marketing experience in the diagnostics sector. He most recently worked for Alere Inc. in Africa for 11 years before retiring in 2017. At Alere he held a range of executive posts including President of Africa, President Commercial Operations for Africa, and Business Development Director for Africa; and led the introduction and successful commercialisation of a number of key HIV screening and HIV patient management point of care diagnostics technologies.
Prior to joining Alere Inc., Tom held senior commercial roles at Trinity Biotech (Ireland) including Marketing and Sales Director (Global) and Business Development Director for Africa, Middle East and India. Trinity Biotech specialises in the development, manufacture and marketing of diagnostic test kits.
Tom studied Microbiology at Glasgow Caledonian University and completed a National Diploma in Microbiology at the South African Institute of Medical Research in Johannesburg, South Africa.
Non-executive Director, Chairman of the Audit Committee
Chris was appointed to Board on 22 August 2018. He is currently CEO of Abingdon Health plc, a position he has held since July 2015. Chris co-founded Abingdon in 2008 and was a non-executive of the company prior to his appointment as CEO. Chris has over 20 years experience of working in listed environments and prior to working at Abingdon, was CFO at Immunodiagnostic Systems Holdings PLC and Cozart plc. Chris is a Chartered Accountant and has a degree in economics from Cambridge University.